How long does it take for Fam-trastuzumab deruxtecan-nxki to work?

Fam-trastuzumab deruxtecan-nxki) is a drug that targets HER2-positive breast cancer. It is an antibody drug combined with chemotherapy drugs for the treatment of advanced or metastatic HER2-positive breast cancer, gastric cancer, and non-small cell lung cancer. The time it takes for the drug to take effect varies from individual to individual. Generally, patients may see some response within a few weeks of starting treatment. However, the full effects of the drug may take longer to manifest, often requiring a treatment cycle of several months.

While trastuzumab has not been tested in larger trials and has potential adverse events, the progression-free survival (PFS) it showed of approximately10 months is a significant advantage over other drugs with a PFS of 5 months. Additionally, the overall survival difference of 23.4 months compared to 16 months with the other drugs was another significant and clinically meaningful finding. Although trastuzumab cannot completely eradicate cancer and cannot be called a cure, given its powerful efficacy and groundbreaking effects, it may prove to be an effective alternative to standard chemotherapy, which targets not only cancer cells but also healthy cells.

Detrastuzumab is a new type of injectable anti-cancer drug. The original drug has been marketed in China, but it has not yet entered the scope of medical insurance. It is a strictly controlled drug. The domestic price is not yet clear. The Hong Kong version of Detrastuzumab Specifications may cost more than 10,000 yuan per box of 100mg. The Hong Kong original version of Detrastuzumab may be more than RMB 10,000 per box. Tocilizumab Specifications of the original drugThe price of 100mg per box may be around 15,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the two drugs are basically the same. There is currently no generic version of trastuzumab on the market. For more specific prices and drug information, please consult the medical consultant of the drug.